Pfizer Pharmaceutical Company: The World's Largest Pharmaceutical Company

Pfizer Licensing, Development & Alliances
Our Partners

"We want to be the first company that researchers in academia, hospitals and biotech companies think of to collaborate with. Our message is a simple one, please call us with your ideas."
- Martin Mackay, President, Pfizer Global Research & Development

We are committed to bringing the best medicines to market. But we know we can't do it alone. That's why we rely on partners to help us supplement our pipeline and capabilities across the entire spectrum of a product's lifecycle, from discovery research through clinical development and ultimately to patients.

Now more than ever, we are seeking new and creative ways to work with partners. We are open to a diverse array of opportunities including partnerships with academia, industry and investors; global and regional deals; as well as agreements for large and small molecules, devices, diagnostics and technologies.

Historically, many of our best-known products began with deals. By 2010, we expect two of every six new products we launch to have originated outside Pfizer.

We have an aggressive goal. You may have what we're looking for. Let's work together to turn your discoveries into tomorrow's cures.

Please click here to view additional companies that we work with.

Looking for a Pfizer Product?
A B-D E-H
I-N O-P R-Z
A-B C D-E
F-L M-P R-U V-Z
Partnering Groups
Partnering Opportunity & Requests
What Our Partners Say About Us

"Pfizer is an important partner and licensee of XOMA's bacterial cell expression technology - they understand the value of our intellectual property, appreciate the needs and interests specific to our organization, and helped structure the deal in a way that maximized the value to both parties. We enjoy working with Pfizer -- from the scientists to the deal-makers to the management -- and look forward to exploring expanded partnership opportunities in the future."

Steven Engle, Chief Executive Officer and President, XOMA

"Pfizer's R&D team did an extraordinary job in keeping in touch with BioRexis as we developed our technology platform and moved our lead drug into the clinic. And when it came time to discuss a potential acquisition, Pfizer assembled a superb team to expeditiously complete comprehensive IP and technical due diligence, then move our transaction forward. As a former lawyer, I was truly impressed by the speed at which our transaction came together. Pfizer was direct and fair in their negotiations with BioRexis, and kept to every commitment they made to us, including following their own very aggressive timetable. It was a real pleasure to work with them."

David R. King, BioRexis

"Pfizer is an important partner and licensee of XOMA's bacterial cell expression technology - they understand the value of our intellectual property, appreciate the needs and interests specific to our organization, and helped structure the deal in a way that maximized the value to both parties. We enjoy working with Pfizer -- from the scientists to the deal-makers to the management -- and look forward to exploring expanded partnership opportunities in the future."

Steven Engle, Chief Executive Officer and President, XOMA

"PowderMed has created a unique needle free technology for delivering DNA based vaccines that has the potential to revolutionize vaccines as we currently know them. Pfizer has the resource, skills and commitment to take this exciting technology and commercialize products to provide the world with the next generation vaccines for prevention and treatment of disease..."

Brenda Reynolds, Chief Operations Officer, PowderMed Ltd

"The negotiations were conducted in a friendly atmosphere with a genuine effort to persevere and creatively overcome the difficulties. We were particularly impressed with Pfizer's teamwork, the excellence and the professionalism with which all team members, regardless of seniority, contributed to the overall endeavor... We at Quark feel that we entrusted our potential drug in the hands of a company that will nurture it and take it in the best possible way down the torturous route of drug development. At the same time, we are confident that Pfizer will continue to treat us as a real partner in overcoming the challenges that lie ahead. Undoubtedly, should the opportunity arise, Pfizer would be our first choice for the licensing partner of our next drug."

Daniel Zurr, President and CEO, Quark Biotech Inc

"Pfizer has been very flexible to accept the different structure of Schwarz. We have been enjoying the highly developed cross-cultural awareness and understanding. The joint teams anticipated many internal and external issues and managed them well at every stage along the process."

Andrea Schuetz, Senior Director International Project Management, Schwarz Pharma

"From our first interaction with Pfizer it was clear that they understood the dynamics of a small Biotechnology company. They applied their learning from previous acquisitions and were able to respond quickly as the deal progressed. We are excited to have become an integral part of Pfizer as we move into an era of increased emphasis on Biotherapeutics to provide a new stream of innovative medicines to meet the needs of patients everywhere."

Carol Stratford, VP and Rinat Site Head